Matchpoint raises $150M to take an oral T cell drug into the clinic in 2027
Nextech Invest and Norwest co-led the Series B for the Watertown, Mass., covalent drug developer. The round brings the equity Matchpoint has disclosed raising to about $250 million, not counting Novartis payments.

- Amount
- $150M
- Type
- Series B
- Company
- Matchpoint Therapeutics
- Led by
- Nextech Invest, Norwest
- Sector
- Biotech
- Announced
- Oct. 7, 2026
Matchpoint Therapeutics has spent the years since its 2022 launch building a platform for covalent small-molecule drugs. With a $150 million Series B announced Oct. 7, the Watertown, Mass., company now has the money to take its first program into people.
Nextech Invest and Norwest co-led the round. New investors Invus, BB Biotech, T1D Fund and BOLD Longevity Growth joined, as did founding investors Access Biotechnology and Atlas Venture, Series A lead Sanofi Ventures, Digitalis Ventures and the company's other existing backers. Matchpoint did not disclose a valuation.
Why it matters: The round is a large bet on pills for autoimmune disease, made before the company's lead drug has entered clinical testing. Matchpoint says MPT-062 is an oral T cell modulator, and the money is meant to carry it from the start of clinical development in 2027 to clinical proof of concept.
Kanishka Pothula, managing partner at Nextech Invest, and Brian Matesic, a principal at Norwest, will join the board, the company said.
The lead program
Matchpoint said the proceeds will take MPT-062 to clinical proof of concept and pay for work on the rest of its pipeline. It has not disclosed the drug's target or the diseases it plans to test first.
"We are deeply grateful to our new and existing investors for their support as we advance MPT-062 into clinical development," Andre Turenne, Matchpoint's chief executive, said in the announcement.
The company says it designs covalent small molecules aimed at targets whose biology is validated but which have historically been hard to drug. It says its discovery engine draws on structure-based drug design, computational work, covalent chemistry and chemical biology.
A Novartis deal on the side
Matchpoint will also keep working on a separate program paid for by Novartis under a July 2025 agreement. At the time, Matchpoint said Novartis had taken an exclusive option on oral covalent inhibitors aimed at a transcription factor tied to several inflammatory diseases. Matchpoint could receive as much as $60 million in combined upfront and research payments, and up to $1 billion in all, counting an option exercise fee and milestones tied to development and sales, plus tiered royalties. If Novartis exercises the option, it would hold global rights to products from the collaboration.
How the money adds up
Matchpoint launched publicly in October 2022 in Cambridge, Mass., with $100 million: a $70 million Series A led by Sanofi Ventures and a $30 million seed round co-led by Atlas Venture and Access Biotechnology in November 2021. Based on those announcements, the Series B lifts the equity Matchpoint has disclosed raising to about $250 million, not counting payments from Novartis.
What to watch
The next marker is the start of MPT-062's clinical development, which Matchpoint has set for 2027. The company has not said where the first trial will run, which indication it will target or when it expects proof-of-concept data. Matchpoint also has not disclosed when Novartis must decide whether to exercise its option.



